key: cord-0693662-h6ulmpnb
authors: Suryatma, A.; Anasi, R.; Hananto, M.; Hermawan, A.; Ramadhany, R.; Indalao, I. L.; Agustiningsih, A.; Fikriyah, E. H.; Tejayanti, T.; Rustika, R.; Tobing, K. L.; Suarjaya, K.; Widia, I. W.; Dhewantara, P. W.
title: Effectiveness of the inactivated COVID-19 vaccine (CoronaVac) in adult population in Indonesia
date: 2022-02-04
journal: nan
DOI: 10.1101/2022.02.02.22270351
sha: 80d391b6afa9ab14e2fbeb55df5e898d6f5a28cd
doc_id: 693662
cord_uid: h6ulmpnb

Abstract Background: Inactivated SARS-CoV-2 vaccine has been included in the national COVID-19 vaccination program in Indonesia since January 2021. The study aims to estimate the effectiveness of CoronaVac vaccine in preventing SARS-CoV-2 infection, hospitalization, and death in adult population aged [≥]18 years in Bali, Indonesia. Methods: Test-negative, case control study was conducted by linking SARS-CoV-2 laboratory records, COVID-19 vaccination, and health administrative data for the period of January 13 to June 30, 2021, among adults aged [≥]18 years in Bali. Case-subjects were defined as individuals who had a positive RT-PCR test for SARS-CoV-2 during the period; they were matched with controls based on age, sex, district of residence, presence of comorbidities and week of testing. Conditional and multivariable logistic regression was performed to estimate adjusted vaccine effectiveness. Results: Adjusted vaccine effectiveness (VE) against laboratory-confirmed SARS-CoV-2 infection was 14.5% (95% confidence interval -11 to 34.2) at 0-13 days after the first dose; 66.7% (58.1 to 73.5%) at [≥]14 days after the second dose. Adjusted VE in preventing hospitalization and COVID-19-associated death was 71.1% (62.9% to 77.6%) and 87.4% (65.1% to 95.4%) at [≥]14 days after receiving the second dose, respectively. Conclusions: Two-dose of inactivated CoronaVac vaccine showed high effectiveness against laboratory confirmed COVID-19 infection, hospitalization, and death associated with COVID-19 among adults aged [≥]18 years.

); 1.2 million (43.1%) had received at least one dose of inactivated CoronaVac 95 vaccine. 9 The observation was conducted during January 13 to June 30, 2021. During the 96 study period, the incidence of COVID-19 was increased during January-February and 97 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 followed with a declining trend from March to June 2021. There was a sharp increase in 98 incidence in July due to B.1.617.2 (Delta) variants (Supplementary Figure S2 , Figure S3 ). 99 We conducted a record-based retrospective, test-negative, matched case control (1:1) study 100 to evaluate the effectiveness of inactivated CoronaVac vaccine in preventing laboratory 101 confirmed SARS-CoV-2 infection, among adults (aged 18 years) during January to June 102 2021. This test negative design was chosen due to several reasons. First, accessibility to 103 individual data who were laboratory-tested for SARS-CoV-2 was feasible through the 104 national surveillance system; second, it was cost-effective and allowed for faster results; and 105 lastly, the design could better control for potential biases, including healthcare seeking 106 behavior and access to COVID-19 testing. 10 107 108 Data sources 109 We linked individual health electronic databases including SARS-CoV-2 reverse-transcription 110 polymerase chain reaction (RT-PCR) test results from the national laboratory testing database 111 (New All Record), COVID-19 vaccination registry, and hospitalization claims, managed by the 112 Ministry of Health of Indonesia, using unique national citizen identification number. Data with 113 foreign identification number and driving license number were excluded. We also checked the 114 consistency in identification number, name, date of birth and sex between these databases.

Confirmatory SARS-CoV-2 PCR test was performed on naso and/or oropharyngeal swab 116 specimens in COVID-19 reference laboratories. 11

Selection of cases and matched controls 119 Cases were adults aged 18 years identified as those who had at least one COVID-19-like 120 symptom (fever with body temperature documented at ≥38°C, chills, cough, shortness of 121 breath, fatigue or malaise, sore throat, headache, runny nose, congestion, muscle aches, nausea 122 or vomiting, diarrhea, abdominal pain, altered sense of smell or taste) and were tested RT-PCR 123 positive for SARS-CoV-2, between January 13 to June 30, 2021; were not confirmed as positive 124 for SARS COV2 in the last 90 days (about 3 months) before the index date; and those who did 125 not receive any COVID-19 vaccines other than CoronaVac before sample collection. Controls 126 were defined as those who had negative RT-PCR test results during the same period, 127 irrespective for symptoms; and who did not receive any COVID-19 vaccines other than 128 CoronaVac before sample collection. Cases and control were matched based on age, sex, district 129 of residence and week of sample collection/testing. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint infection. There was a considerable proportion of missing data for comorbidities (79%).

Multiple imputation was performed with considering for covariates (age, sex, residence) and 146 outcome. Vaccine effectiveness (VE) was calculated as one minus the OR multiplied by 100%. Characteristics of the study population and matched case-control were presented in Table 1 .

The median age of the overall study population (n=14,168) was 50 years (interquartile range, 163 31-65 years); 50.8% were aged 50 years. Thirty percent (n=4259) resided in Denpasar city. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint sample size and small number of events (mortality). Among older population, vaccine 190 effectiveness was 90.6% (95%CI:61.5-97.7%) in preventing death due to To address potential issues related to the small sample size and rare event or outcome, we 192 conducted an additional analysis using study population (n=14,168) (Supplementary Table S3 , 193 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint respectively. 7 This discrepancy might be due to several factors including variation in study 232 population and design (e.g., targeted age group, sample size) and difference in risk of 233 transmission or epidemiological setting (e.g., a TND study in Brazil was conducted when P.1 234 or Gamma variant was predominant).

The strengths of this study are that: i) we used comprehensive health administrative database However, our study has limitations. First, while we attempted to make a robust approach by 243 adjusting for number of potential confounding factors, including age, sex, geography, week of 244 testing (sample collection) and presence of comorbidities, there might be still unmeasured 245 confounding factors that biased the VE estimates (e.g., behavioral risk factors, type of variants).

Second, this study was retrieved data from January to June 2021, which was just before the is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.02.22270351 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.02.22270351 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.02.22270351 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.02.22270351 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.02.22270351 doi: medRxiv preprint

*Based on adjusted multivariable logistic regression, accounting for age (continuous), sex, district of COVID-19 in adults (aged 18 years), by age group

COVID-19 vaccination coverage in adults 18 years (any type of vaccines) during

Indonesia (Data source: Ministry of Health of Indonesia)

Trends in COVID-19 incidence in Bali over the period of study (Data source: Ministry 622 of Health of Indonesia)

Distribution of SARS-CoV-2 variants of concern (VOCs) in samples examined during 632

Variant proportions are estimated against total sequences of 633 collected samples of each month. Total samples are varied for each month. Data are subject to change 634 over time and will be updated as more data become available. Variant proportions may not represent 635 national estimates

Data source: Ministry of Health of Indonesia)